Orthocell Ltd
ASX:OCC

Watchlist Manager
Orthocell Ltd Logo
Orthocell Ltd
ASX:OCC
Watchlist
Price: 1.285 AUD -1.91%
Market Cap: 307.3m AUD
Have any thoughts about
Orthocell Ltd?
Write Note

Orthocell Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Orthocell Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Orthocell Ltd
ASX:OCC
Cash Equivalents
AU$20.6m
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Cash Equivalents
AU$35.2m
CAGR 3-Years
-25%
CAGR 5-Years
-8%
CAGR 10-Years
9%
Telix Pharmaceuticals Ltd
ASX:TLX
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cash Equivalents
AU$66.9m
CAGR 3-Years
54%
CAGR 5-Years
61%
CAGR 10-Years
32%
No Stocks Found

Orthocell Ltd
Glance View

Market Cap
307.3m AUD
Industry
Biotechnology

Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.

OCC Intrinsic Value
1.893 AUD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Orthocell Ltd's Cash Equivalents?
Cash Equivalents
20.6m AUD

Based on the financial report for Jun 30, 2024, Orthocell Ltd's Cash Equivalents amounts to 20.6m AUD.

What is Orthocell Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
13%

Over the last year, the Cash Equivalents growth was -17%. The average annual Cash Equivalents growth rates for Orthocell Ltd have been 8% over the past three years , 13% over the past five years .

Back to Top